ADB-BUTINACA (also known as ADMB-BINACA using EMCDDA naming standards[3]) is a synthetic cannabinoid compound which has been sold as a designer drug.

[4][5][6][7][8] It is a potent CB1 agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC50 of 6.36 nM for CB1.

[9][10][11][12][13][14][15]